Literature DB >> 27696317

Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation.

Erin A Fender1, Jawad G Kiani1, David R Holmes2.   

Abstract

PURPOSE OF REVIEW: Anticoagulant therapy effectively reduces the incidence of stroke in patients with atrial fibrillation (AF) but is underutilized and frequently contraindicated. The left atrial appendage (LAA) is the primary site of thrombus formation in AF patients. Surgical and percutaneous appendage closure has been evaluated as a site-specific therapy to reduce systemic thromboembolism. RECENT
FINDINGS: We will review LAA closure techniques, examine recent outcome data, and discuss the indications for, and potential complications of, each approach. Randomized data examining surgical LAA closure and epicardial closure with the LARIAT device are lacking. High quality, randomized data supports the efficacy of the WATCHMAN device for stroke prevention in patients with AF.

Entities:  

Keywords:  Atrial fibrillation; Lariat; Left atrial appendage closure; Stroke; Watchman

Mesh:

Substances:

Year:  2016        PMID: 27696317     DOI: 10.1007/s11883-016-0616-z

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  32 in total

1.  Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography.

Authors:  Anne S Kanderian; A Marc Gillinov; Gosta B Pettersson; Eugene Blackstone; Allan L Klein
Journal:  J Am Coll Cardiol       Date:  2008-09-09       Impact factor: 24.094

2.  Thoracoscopic stand-alone left atrial appendectomy for thromboembolism prevention in nonvalvular atrial fibrillation.

Authors:  Toshiya Ohtsuka; Mikio Ninomiya; Takahiro Nonaka; Motoyuki Hisagi; Takahiro Ota; Toru Mizutani
Journal:  J Am Coll Cardiol       Date:  2013-02-20       Impact factor: 24.094

3.  Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials.

Authors:  Stefan H Ostermayer; Mark Reisman; Paul H Kramer; Ray V Matthews; William A Gray; Peter C Block; Heyder Omran; Antonio L Bartorelli; Paolo Della Bella; Carlo Di Mario; Carlo Pappone; Paul N Casale; Jeffrey W Moses; Athena Poppas; David O Williams; Bernhard Meier; Allan Skanes; Paul S Teirstein; Michael D Lesh; Toshiko Nakai; Yves Bayard; Kai Billinger; Thomas Trepels; Ulrike Krumsdorf; Horst Sievert
Journal:  J Am Coll Cardiol       Date:  2005-07-05       Impact factor: 24.094

Review 4.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

5.  Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry.

Authors:  Vivek Y Reddy; David Holmes; Shephal K Doshi; Petr Neuzil; Saibal Kar
Journal:  Circulation       Date:  2011-01-17       Impact factor: 29.690

6.  Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience.

Authors:  Krzysztof Bartus; Frederick T Han; Jacek Bednarek; Jacek Myc; Boguslaw Kapelak; Jerzy Sadowski; Jacek Lelakowski; Stanislaw Bartus; Steven J Yakubov; Randall J Lee
Journal:  J Am Coll Cardiol       Date:  2012-10-10       Impact factor: 24.094

7.  Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.

Authors:  David R Holmes; Saibal Kar; Matthew J Price; Brian Whisenant; Horst Sievert; Shephal K Doshi; Kenneth Huber; Vivek Y Reddy
Journal:  J Am Coll Cardiol       Date:  2014-07-08       Impact factor: 24.094

8.  Initial experience with a novel percutaneous left atrial appendage exclusion device in patients with atrial fibrillation, increased stroke risk, and contraindications to anticoagulation.

Authors:  Ali Massumi; Mihail Gabriel Chelu; Alireza Nazeri; Stephen Allen May; Hamid Afshar-Kharaghan; Mohammad Saeed; Mehdi Razavi; Abdi Rasekh
Journal:  Am J Cardiol       Date:  2013-01-09       Impact factor: 2.778

9.  Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium.

Authors:  Matthew J Price; Douglas N Gibson; Steven J Yakubov; Jason C Schultz; Luigi Di Biase; Andrea Natale; J David Burkhardt; Ashish Pershad; Timothy J Byrne; Brett Gidney; Joseph R Aragon; Jeffrey Goldstein; Kriegh Moulton; Taral Patel; Bradley Knight; Albert C Lin; Miguel Valderrábano
Journal:  J Am Coll Cardiol       Date:  2014-08-12       Impact factor: 24.094

10.  Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis.

Authors:  David R Holmes; Shephal K Doshi; Saibal Kar; Matthew J Price; Jose M Sanchez; Horst Sievert; Miguel Valderrabano; Vivek Y Reddy
Journal:  J Am Coll Cardiol       Date:  2015-06-23       Impact factor: 27.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.